{"nctId":"NCT01857622","briefTitle":"Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment","startDateStruct":{"date":"2011-11"},"conditions":["Non-valvular Atrial Fibrillation"],"count":93,"armGroups":[{"label":"SRI 15mg","type":"EXPERIMENTAL","interventionNames":["Drug: DU-176b 15mg"]},{"label":"Normal/MiRI low-dose group","type":"EXPERIMENTAL","interventionNames":["Drug: DU-176b 30mg"]},{"label":"Normal/MiRI high-dose group","type":"EXPERIMENTAL","interventionNames":["Drug: DU-176b 60mg"]}],"interventions":[{"name":"DU-176b 15mg","otherNames":["edoxaban"]},{"name":"DU-176b 30mg","otherNames":["edoxaban"]},{"name":"DU-176b 60mg","otherNames":["edoxaban"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI.\n\nExclusion Criteria:\n\n* Patients who are on hemodialysis or patients who may start hemodialysis before the follow-up assessment\n* Patients who are at a significantly high risk for bleeding\n* Patients who are receiving treatment with any anticoagulant drugs excluding warfarin, rivaroxaban, and dabigatran\n* Patients who have evidence of hepatic function test abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Any Adjudicated Bleeding Events","description":"Incidence of any adjudicated bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"22.7","spread":null},{"groupId":"OG002","value":"23.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":50},"commonTop":["nasopharyngitis","haematuria","Haemorrhage subcutaneous","gingival bleeding","Blood creatinine increased"]}}}